Boston Scientific reported strong Q3 2024 financial results with net sales reaching $4.209 billion, up 19.4% on a reported basis and 18.2% organically year-over-year. The company achieved GAAP EPS of $0.32 and adjusted EPS of $0.63, exceeding guidance. Cardiovascular segment led growth with 25% increase, while MedSurg segment grew 10.3%.The company demonstrated robust regional performance, with U.S. sales growing 23.5%, EMEA up 15.2%, and APAC increasing 12.1%. Notable achievements include FDA approval for FARAWAVE NAV Ablation Catheter, PMDA approval in Japan for FARAPULSE PFA System, and completion of Silk Road Medical acquisition.Based on strong performance, Boston Scientific raised its full-year 2024 guidance, now expecting approximately 16.5% reported net sales growth and 15% organic growth. The company projects full-year adjusted EPS of $2.45-$2.47, and Q4 2024 reported net sales growth of 16.5-18.5% with organic growth of 14-16%.

Boston Scientific reported strong Q3 2024 financial results with net sales reaching $4.209 billion, up 19.4% on a reported basis and 18.2% organically year-over-year. The company achieved GAAP EPS of $0.32 and adjusted EPS of $0.63, exceeding guidance. Cardiovascular segment led growth with 25% increase, while MedSurg segment grew 10.3%.The company demonstrated robust regional performance, with U.S. sales growing 23.5%, EMEA up 15.2%, and APAC increasing 12.1%. Notable achievements include FDA approval for FARAWAVE NAV Ablation Catheter, PMDA approval in Japan for FARAPULSE PFA System, and completion of Silk Road Medical acquisition.Based on strong performance, Boston Scientific raised its full-year 2024 guidance, now expecting approximately 16.5% reported net sales growth and 15% organic growth. The company projects full-year adjusted EPS of $2.45-$2.47, and Q4 2024 reported net sales growth of 16.5-18.5% with organic growth of 14-16%.